Ferroquine/ Artefenomel

Sanofi

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management

MoA
  • Ferroquine (FQ), belonging to 4-aminoquinolines: inhibition of haem detoxification
  • Artefenomel (OZ439): novel, synthetic trioxolane
Key features

Ferroquine

  • Long duration of plasma exposure

Artefenomel

  • Fast killing of parasites

  • 800mg human dose stays above Minimal Parasiticidal Concentration for >8 days

  • Transmission-blocking activity in a Standard Membrane Feeding Assay

Challenges
  • OZ439 food effect/formulation

Status
  • Phase llb combination study recruitment was completed in July 2019

Next milestone
  • Phase IIb study completion

Previously
  • In 2018 Sanofi transfered the operational responsibility for R&D to MMV
  • Ferroquine discovery: CNRS
  • Artefenomel discovery: partnership MMV, Monash University, University of Nebraska and Swiss TPH
MMV Project Director
  • Dr Florian Wartha